AxoGen, Inc. (AXGN) Cash Flow Statement

NASDAQ: AXGNOperating cash, capex, free cash flow and buybacks.

Where AXGN’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
$812,000
−82.1% vs 2024
Capital expenditures
$3.7M
1.7% of revenue
Free cash flow
−$2.9M
−1.3% margin
Returned to shareholders
—
Change in cash
$6.0M
cash at year-end $39.5M
Cash from operations: $812,000Cash from operations$812,000Other financing: $10.5MOther financing$10.5MInvestments (net): $277,000Investments (net)$277,000Capital expenditures: $3.7MCapital expenditures$3.7M · 32%Acquisitions & other: $1.8MAcquisitions & other$1.8M · 16%Added to cash: $6.0MAdded to cash$6.0M · 52%Debt repayment: $32,000Debt repayment$32,000 · 0%$11.6M
Cash from operations
$812,000
Capital expenditures
−$3.7M
Investments (net)
+$277,000
Acquisitions & other
−$1.8M
Net borrowing (repayment)
−$32,000
Other financing
+$10.5M
Change in cash
$6.0M

Drawn to scale: where the cash came from and how it was used. Hover for values.

AXGN operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

AXGN cash flow trends, 2016–2025

AxoGen, Inc. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$11.2M2016$812,0002025—
Capital expenditures$1.2M2016$3.7M2025+13.6%/yr
Free cash flow−$12.4M2016−$2.9M2025—
Free cash flow margin−30.2%2016−1.3%2025+28.8 pts
Stock-based compensation$1.4M2016$30.1M2025+40.7%/yr
Dividends paid$02016$670,0002020—
Share buybacks (net)$02016$02022—
Capex / revenue2.9%20161.7%2025−1.2 pts

Change is the average annual growth (CAGR) or the difference between the first and latest year.

AXGN cash flow by activity

OperatingInvestingFinancingChange in cash

AXGN net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

AXGN cash flow statement

AxoGen, Inc. annual cash flow statement
2025202420232022202120202019201820172016
Operating activities
Net income−$15.7M−$10.0M−$21.7M−$28.9M−$27.0M−$23.8M−$29.1M−$22.4M−$10.4M−$14.4M
Depreciation & amortization$8.2M$7.8M$5.6M$4.9M$4.7M$3.5M$2.9M$851,000$566,604$436,488
Stock-based compensation$30.1M$15.9M$14.4M$15.6M$10.9M$8.5M$10.3M$7.6M$3.6M$1.4M
Change in working capital−$24.6M−$10.0M−$4.4M−$9.6M−$6.3M−$209,000−$5.4M−$8.4M−$3.4M−$1.5M
Other non-cash items$2.8M$797,000$415,000$2.0M$4.2M$2.4M$1.5M$4.5M$469,880$2.9M
Cash from operating activities$812,000$4.5M−$5.7M−$16.1M−$13.4M−$9.6M−$19.9M−$17.9M−$9.2M−$11.2M
Investing activities
Capital expenditures−$3.7M−$4.5M−$14.9M−$21.3M−$28.4M−$22.6M−$5.2M−$6.6M−$1.3M−$1.2M
Investments (net)$277,000−$10.3M$18.3M$18.1M$3.8M$5.6M$27.3M−$91.6M−$1.3M−$1.2M
Acquisitions & other investing−$1.8M$4.5M$15.8M$0$950,000$0$5.2M$0$1.3M$1.2M
Cash from investing activities−$5.3M−$10.3M$19.3M−$3.2M−$23.6M−$17.0M$27.3M−$98.2M−$1.3M−$1.2M
Financing activities
Dividends paid—————−$670,000——$0$0
Share repurchases & issuance (net)———$1.8M$5.5M−$670,000$4.0M$136.6M$17.1M$19.7M
Net borrowing (repayment)−$32,000−$10,000−$10,000−$12,000$15.0M$35.0M$29,000−$26.7M−$75,394−$3.2M
Shares issued$0$0$0$0$0$3.5M$7.8M$133.0M$0$0
Other financing$10.5M$2.3M$2.0M$0$0$3.3M−$7.8M−$133.0M$0$0
Cash from financing activities$10.5M$2.3M$2.0M$1.8M$20.5M$40.5M$4.0M$109.8M$17.0M$16.5M
Summary
Net change in cash$6.0M−$3.5M$15.5M−$17.5M−$16.6M$13.9M$11.4M−$6.2M$6.5M$4.1M
Cash at end of period$39.5M$33.6M$37.0M$21.5M$39.0M$55.6M$41.7M$30.3M$36.5M$30.0M
Free cash flow−$2.9M$11,000−$20.6M−$37.3M−$41.8M−$32.2M−$25.1M−$24.5M−$10.5M−$12.4M
Free cash flow margin−1.3%0.0%−13.0%−26.9%−32.8%−28.7%−23.5%−29.1%−17.4%−30.2%
Capex / revenue1.7%2.4%9.4%15.3%22.3%20.1%4.9%7.9%2.1%2.9%

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

AXGN cash generation

In fiscal 2025 (ended December 31, 2025), AxoGen generated $0.8 million of cash from operations (down 82.1%) and spent $3.7 million on capital expenditures, leaving free cash flow of -$2.9 million, −1.3% of revenue. Cash and equivalents rose by $6.0 million over the year.

Related: AXGN income statement, AXGN balance sheet. See the AXGN stock overview for the latest quote and news.

AXGN cash flow FAQ

What is AxoGen's free cash flow?

AxoGen's free cash flow was -$2.9 million in fiscal 2025: $0.8 million of operating cash flow minus $3.7 million of capital expenditures It was $0.0 million a year earlier..

How much cash does AxoGen generate from operations?

AxoGen generated $0.8 million of cash from operating activities in fiscal 2025.

How much does AxoGen spend on capital expenditures?

AxoGen spent $3.7 million on capital expenditures in fiscal 2025, 1.7% of revenue, compared with $4.5 million the year before.

Medical Devices: cash flow